Incyte Stock Buy Hold or Sell Recommendation
| INCY Stock | USD 70.42 0.41 0.59% |
Given the investment horizon of 90 days and your above-average risk tolerance, our recommendation regarding Incyte is 'Cautious Hold'. A buy or sell recommendation is an automated directive regarding whether to purchase or sell Incyte given historical horizon and risk tolerance. When we issue a 'buy' or 'sell' recommendation for Incyte, the advice is generated through an automated system that utilizes algorithms and statistical models.
Check out Incyte Analyst Recommendation to compare Macroaxis Buy or Sell Recommendation with the current analyst consensus. To check ratings for multiple equity instruments, please use the Instant Ratings tool. For more information on how to buy Incyte Stock please use our How to Invest in Incyte guide. In addition, we conduct extensive research on individual companies such as Incyte and provide practical buy, sell, or hold advice based on investors' investing horizon and their risk tolerance towards Incyte. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in main economic indicators.
Incyte |
Execute Incyte Buy or Sell Advice
The Incyte recommendation should be used to complement the buy-or-sell advice compiled from the current analysts' consensus on Incyte. Macroaxis does not own or have any residual interests in Incyte or other equities on which the buy-or-sell advice is provided. Please provide your input below to execute Incyte's advice using the current market data and latest reported fundamentals.
Time Horizon
Risk Tolerance
 |  |
Cautious Hold
Market Performance | Very Weak | Details | |
Volatility | Very steady | Details | |
Hype Condition | Low key | Details | |
Current Valuation | Undervalued | Details | |
Odds Of Distress | Very Low | Details | |
Economic Sensitivity | Slowly supersedes the market | Details | |
Investor Sentiment | Alarmed | Details | |
Analyst Consensus | Buy | Details | |
Financial Strenth (F Score) | Strong | Details | |
Financial Leverage | Not Rated | Details | |
Reporting Quality (M-Score) | Possible Manipulator | Details |
Incyte Trading Alerts and Improvement Suggestions
| Incyte generated a negative expected return over the last 90 days | |
| Incyte has a strong financial position based on the latest SEC filings | |
| Over 97.0% of the company shares are owned by institutional investors | |
| Latest headline from finance.yahoo.com: Companion Diagnostics Market Trends 2019-2024 and Forecast to 2034 - Rising Number of Targeted Therapies Driving the 8.75 Billion Industry |
Incyte Returns Distribution Density
The distribution of Incyte's historical returns is an attempt to chart the uncertainty of Incyte's future price movements. The chart of the probability distribution of Incyte daily returns describes the distribution of returns around its average expected value. We use Incyte price's Value At Risk and its Upside Potential as a relative measure of the distribution. The graph of the distribution of Incyte returns is essential to provide solid investment advice for Incyte.
| Mean Return | -0.23 | Value At Risk | -3.54 | Potential Upside | 2.65 | Standard Deviation | 2.25 |
Return Density |
| Distribution |
Investment risk management requires an estimate of the probability of extreme price changes. Therefore, the correct representation of the distribution of Incyte historical returns presented in an easy-to-digest graphical form helps investors and money managers understand the risk-reward trade-off of different investement strategies.
Incyte Stock Institutional Investors
Have you ever been surprised when a price of an equity instrument, such as Incyte, soars without any apparent reason? This usually happens because many institutional investors are aggressively trading Incyte back and forth among themselves.
| Shares | Armistice Capital, Llc | 2024-09-30 | 2.2 M | Bellevue Group Ag | 2024-09-30 | 2.2 M | Morgan Stanley - Brokerage Accounts | 2024-09-30 | 2.1 M | Mizuho Securities Usa Inc | 2024-09-30 | 2 M | Legal & General Group Plc | 2024-09-30 | 1.7 M | Charles Schwab Investment Management Inc | 2024-12-31 | 1.6 M | Northern Trust Corp | 2024-09-30 | 1.5 M | Dimensional Fund Advisors, Inc. | 2024-09-30 | 1.4 M | Ubs Asset Mgmt Americas Inc | 2024-09-30 | 1.4 M | Baker Bros Advisors Lp | 2024-09-30 | 30.7 M | Vanguard Group Inc | 2024-09-30 | 20.4 M |
Incyte Cash Flow Accounts
| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 (projected) | ||
| Change In Cash | (318.9M) | 544.4M | 894.0M | 262.1M | (1.5B) | (1.4B) | |
| Free Cash Flow | (312.0M) | 568.5M | 892.1M | 449.0M | 249.1M | 261.5M | |
| Depreciation | 51.8M | 57.8M | 67.9M | 82.7M | 89.2M | 93.7M | |
| Other Non Cash Items | 13.5M | 40.2M | 117.1M | 7.9M | 33.0M | 17.5M | |
| Capital Expenditures | 187.4M | 181.0M | 77.8M | 47.5M | 86.3M | 44.6M | |
| Net Income | (295.7M) | 948.6M | 340.7M | 597.6M | 32.6M | 34.2M | |
| End Period Cash Flow | 1.5B | 2.1B | 3.0B | 3.2B | 1.7B | 1.8B | |
| Change To Inventory | (19.5M) | (21.0M) | (67.5M) | (170.2M) | (127.6M) | (134.0M) | |
| Investments | (81.6M) | (26.7M) | (709K) | (74.1M) | 157.5M | 165.4M | |
| Change Receivables | (1.2M) | (173.2M) | (134.3M) | (28.6M) | (25.7M) | (27.0M) | |
| Change To Netincome | 186.4M | 201.5M | (266.4M) | 275.0M | 316.3M | 332.1M |
Incyte Greeks
Most traded equities are subject to two types of risk - systematic (i.e., market) and unsystematic (i.e., nonmarket or company-specific) risk. Unsystematic risk is the risk that events specific to Incyte or Biotechnology sector will adversely affect the stock's price. This type of risk can be diversified away by owning several different stocks in different industries whose stock prices have shown a small correlation to each other. On the other hand, systematic risk is the risk that Incyte's price will be affected by overall stock market movements and cannot be diversified away. So, no matter how many positions you have, you cannot eliminate market risk. However, you can measure a Incyte stock's historical response to market movements and buy it if you are comfortable with its volatility direction. Beta and standard deviation are two commonly used measures to help you make the right decision.
α | Alpha over Dow Jones | -0.24 | |
β | Beta against Dow Jones | 0.39 | |
σ | Overall volatility | 2.26 | |
Ir | Information ratio | -0.11 |
Incyte Volatility Alert
Incyte exhibits very low volatility with skewness of -1.29 and kurtosis of 3.24. Understanding different market volatility trends often help investors to time the market. Properly using volatility indicators enable traders to measure Incyte's stock risk against market volatility during both bullish and bearish trends. The higher level of volatility that comes with bear markets can directly impact Incyte's stock price while adding stress to investors as they watch their shares' value plummet. This usually forces investors to rebalance their portfolios by buying different financial instruments as prices fall.Incyte Fundamentals Vs Peers
Comparing Incyte's fundamentals to the average values of its peers is one of the most widely used and accepted methods of equity analyses. It helps to analyze Incyte's direct or indirect competition across all of the common fundamentals between Incyte and the related equities. This way, we can detect undervalued stocks with similar characteristics as Incyte or determine the stocks which would be an excellent addition to an existing portfolio. Peer analysis of Incyte's fundamental indicators could also be used in its relative valuation, which is a method of valuing Incyte by comparing valuation metrics with those of similar companies.
| Better Than Average | Worse Than Average | Compare Incyte to competition |
| Fundamentals | Incyte | Peer Average |
| Return On Equity | 0.0075 | -0.31 |
| Return On Asset | 0.0086 | -0.14 |
| Profit Margin | 0.01 % | (1.27) % |
| Operating Margin | 0.25 % | (5.51) % |
| Current Valuation | 11.51 B | 16.62 B |
| Shares Outstanding | 193.52 M | 571.82 M |
| Shares Owned By Insiders | 2.04 % | 10.09 % |
| Shares Owned By Institutions | 96.79 % | 39.21 % |
| Number Of Shares Shorted | 5.79 M | 4.71 M |
| Price To Earning | 19.17 X | 28.72 X |
| Price To Book | 3.95 X | 9.51 X |
| Price To Sales | 3.21 X | 11.42 X |
| Revenue | 4.24 B | 9.43 B |
| Gross Profit | 1.48 B | 27.38 B |
| EBITDA | 408.16 M | 3.9 B |
| Net Income | 32.62 M | 570.98 M |
| Cash And Equivalents | 2.72 B | 2.7 B |
| Cash Per Share | 12.24 X | 5.01 X |
| Total Debt | 37.96 M | 5.32 B |
| Debt To Equity | 0.01 % | 48.70 % |
| Current Ratio | 3.91 X | 2.16 X |
| Book Value Per Share | 17.82 X | 1.93 K |
| Cash Flow From Operations | 335.34 M | 971.22 M |
| Short Ratio | 4.24 X | 4.00 X |
| Earnings Per Share | 0.15 X | 3.12 X |
| Price To Earnings To Growth | 0.45 X | 4.89 X |
| Target Price | 78.26 | |
| Number Of Employees | 2.52 K | 18.84 K |
| Beta | 0.7 | -0.15 |
| Market Capitalization | 13.63 B | 19.03 B |
| Total Asset | 5.44 B | 29.47 B |
| Retained Earnings | (1.07 B) | 9.33 B |
| Working Capital | 1.6 B | 1.48 B |
Note: Acquisition by Flannelly Barry P of 20144 shares of Incyte at 71.93 subject to Rule 16b-3 [view details]
Incyte Market Momentum
Traders often use several daily momentume indicators to supplement a more traditional technical analysis when analyzing securities such as Incyte . With many different options, investors must choose the best indicators for them and familiarize themselves with how they work. We suggest combining traditional momentum indicators with more near-term forms of technical analysis such as Accumulation Distribution or Daily Balance Of Power. With their quantitative nature, daily value technical indicators can also be incorporated into your automated trading systems.
About Incyte Buy or Sell Advice
When is the right time to buy or sell Incyte? Buying financial instruments such as Incyte Stock isn't very hard. However, what challenging for most investors is doing it at the right time to beat the market. Proper market timing is something most people cannot do without sophisticated tools, which help to isolate the right opportunities. Macroaxis provides hands-on modules to deliver winning trades and diversify your portfolios on a daily basis. Most of our advising modules are very easy to use and apply.
Please read more on our stock advisor page.
Use Investing Ideas to Build Portfolios
In addition to having Incyte in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.Did You Try This Idea?
Run Consumption Thematic Idea Now
Consumption
Companies that deliver final goods such as cars or clothing for consumption by consumers. The Consumption theme has 19 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize Consumption Theme or any other thematic opportunities.
| View All Next | Launch |
Additional Tools for Incyte Stock Analysis
When running Incyte's price analysis, check to measure Incyte's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Incyte is operating at the current time. Most of Incyte's value examination focuses on studying past and present price action to predict the probability of Incyte's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Incyte's price. Additionally, you may evaluate how the addition of Incyte to your portfolios can decrease your overall portfolio volatility.